Catch Up on the Latest MBC Research!

[Bestbird]

If you or a loved one has MBC, take a look at the summary of cutting-edge MBC research disclosed at the San Antonio Breast Cancer Symposium (SABCS) in Dec. 2021! There’s encouraging news for individuals with each subtype of MBC, and all information has been incorporated into my book, “The Insider’s Guide to Metastatic Breast Cancer,” which is also available as a complimentary .pdf.

Here’s a sample from the document:

For Patients with TNBC MBC: Datopotamab Deruxtecan (Dato-DXd) is an Antibody Drug Conjugate (ADC) that was studied in the TROPION-PanTumor01 Phase 1 Trial. The 44 patients enrolled in the study had been treated with a median of three prior therapies in the metastatic setting, including taxanes, platinum-based chemotherapy, immunotherapy, other ADCs, and PARP inhibitors. The overall Objective Response Rate (ORR) was 34%, and in the subgroup of 27 patients who had not previously been treated with a TROP-2-directed drug (such as Trodelvy) the ORR was 52%.

Want to see more? Visit: insidersguidembc.com/sabcs

[Hidden]

Thanks Anne for keeping us up to date with news.I will have a read.

Clare

[Hidden]

I would be interested to know that and thanks for highlighting it Sandra.I will ask my Onc when I next get to see her

Clare

[Teddielottie in reply to Hidden]

I have read that NICE Pathways (UK) is being withdrawn in Spring 2022, but will not be updated after 31 December 2021 . This means that from January 2022 the content on NICE Pathways will not reflect all their latest guidance and advice , and some will be removed sooner , to avoid showing out-of -date information on their site .The explanation given is that ‘it is built on old technology, and they are focussing their resources on improving how they create and maintain up-to-date guidance that integrates the latest evidence , practice and technologies in a useful and useable format .’

They are gathering feedback about NICE Pathways to help improve future services , and if you are interested in taking part in this research, you should send your name and email address to [e-mail]

[Hidden in reply to Teddielottie]

Thanks Lesh, that’s really informativeClare

[NPmary]

Thank you Anne, l so appreciate you and your book ❤

[Nature613]

Anne, Thank you for the helpful info. I have your book and you are an inspiration.

[Iwasborntodothis]

Thank you Anne - was anything about PARP being used for other breast cancer subtypes or mutations? My oncologist (Dr A Wendt) was in attendance, he is trying to get me approved for this as my next line of treatment but insurance has denied because I am not BRACA or Triple Neg, just ATM mutation.You are a treasure for all of us!

[Bestbird in reply to Iwasborntodothis]

Nothing specific that I recall re: PARP inhibitors, but you may want to do more checking around. Good luck and kind wishes!

[MyMiracle13]

Thank you for your help.